VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
What is Flush?
Webcast Access Link
Wednesday, September 16, 2020 at 3PM